Trial Profile
A Multicentre, Open label, Balanced, Randomized, Two-treatment, Two-period, Single dose, Crossover, Bioequivalence study of Bortezomib for Injection 3.5 mg/vial of Dr. Reddy's Laboratories Limited, India and VELCADE® (bortezomib) for Injection 3.5 mg/vial (Distributed by: Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139) in previously untreated Multiple Myeloma and/or Relapsed/Refractory Multiple Myeloma patients.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Dr Reddys Laboratories
- 02 Sep 2016 New trial record